Impact of Serum Magnesium Levels on Mineral-Bone Metabolism in Non-Dialysis-Dependent Chronic Kidney Disease.

IF 2.7 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Risk Management and Healthcare Policy Pub Date : 2025-06-08 eCollection Date: 2025-01-01 DOI:10.2147/RMHP.S516474

Yan-Ping Cao, Li-Ping Zhu, Hai-Jiang Ge, Rui-Qing Zhang, Ru-Juan Chen, Bo Yuan, Wei-Jia Shi

{"title":"Impact of Serum Magnesium Levels on Mineral-Bone Metabolism in Non-Dialysis-Dependent Chronic Kidney Disease.","authors":"Yan-Ping Cao, Li-Ping Zhu, Hai-Jiang Ge, Rui-Qing Zhang, Ru-Juan Chen, Bo Yuan, Wei-Jia Shi","doi":"10.2147/RMHP.S516474","DOIUrl":null,"url":null,"abstract":"Background: Magnesium is one of the important minerals in the human body. The metabolic imbalance of magnesium has been found in patients with chronic kidney disease (CKD), but the research on the serum magnesium level of patients with non-dialysis-dependent CKD (NDD-CKD) and its relationship with mineral-skeletal metabolic disorder (CKD-MBD) is still relatively limited. This study aims to explore the changes in serum magnesium levels in patients with non-dialysis-dependent CKD at different stages and evaluate its relationship with mineral metabolism markers (calcium, phosphorus, iPTH and alkaline phosphatase).Methods: A retrospective analysis was conducted on data from 156 patients with stage 3-5 CKD (G3-G5) admitted to Handan First Hospital between March 2017 and December 2019. Serum magnesium, calcium, phosphorus, intact parathyroid hormone (iPTH), and alkaline phosphatase (AKP) levels were analyzed. The patients were categorized into hypomagnesemia, normal magnesium, and hypermagnesemia groups based on serum magnesium levels. Correlations between magnesium levels and phosphorus, iPTH, and AKP levels were analyzed.Results: Serum magnesium levels displayed an upward trend across CKD stages G3 to G5, though this trend was not statistically significant. The prevalence of hypomagnesemia was 0%, 6.82%, and 15.07%, while the incidence of hypermagnesemia was 5.13%, 13.64%, and 30.14% in G3, G4, and G5 stages, respectively. Serum magnesium levels demonstrated a significant positive correlation with serum calcium and the calcium-phosphorus product, whereas no correlation was observed with serum phosphorus or iPTH levels.Conclusion: Magnesium metabolic disorders progressively increase with CKD severity, with the highest prevalence observed in stage G5. These findings indicate that changes in serum magnesium levels may influence the development and progression of CKD-MBDs.","PeriodicalId":56009,"journal":{"name":"Risk Management and Healthcare Policy","volume":"18 ","pages":"1847-1856"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12161143/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Risk Management and Healthcare Policy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/RMHP.S516474","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Magnesium is one of the important minerals in the human body. The metabolic imbalance of magnesium has been found in patients with chronic kidney disease (CKD), but the research on the serum magnesium level of patients with non-dialysis-dependent CKD (NDD-CKD) and its relationship with mineral-skeletal metabolic disorder (CKD-MBD) is still relatively limited. This study aims to explore the changes in serum magnesium levels in patients with non-dialysis-dependent CKD at different stages and evaluate its relationship with mineral metabolism markers (calcium, phosphorus, iPTH and alkaline phosphatase).

Methods: A retrospective analysis was conducted on data from 156 patients with stage 3-5 CKD (G3-G5) admitted to Handan First Hospital between March 2017 and December 2019. Serum magnesium, calcium, phosphorus, intact parathyroid hormone (iPTH), and alkaline phosphatase (AKP) levels were analyzed. The patients were categorized into hypomagnesemia, normal magnesium, and hypermagnesemia groups based on serum magnesium levels. Correlations between magnesium levels and phosphorus, iPTH, and AKP levels were analyzed.

Results: Serum magnesium levels displayed an upward trend across CKD stages G3 to G5, though this trend was not statistically significant. The prevalence of hypomagnesemia was 0%, 6.82%, and 15.07%, while the incidence of hypermagnesemia was 5.13%, 13.64%, and 30.14% in G3, G4, and G5 stages, respectively. Serum magnesium levels demonstrated a significant positive correlation with serum calcium and the calcium-phosphorus product, whereas no correlation was observed with serum phosphorus or iPTH levels.

Conclusion: Magnesium metabolic disorders progressively increase with CKD severity, with the highest prevalence observed in stage G5. These findings indicate that changes in serum magnesium levels may influence the development and progression of CKD-MBDs.

查看原文本刊更多论文

血清镁水平对非透析依赖性慢性肾病患者矿物质骨代谢的影响

背景：镁是人体重要的矿物质之一。慢性肾脏疾病（CKD）患者存在镁代谢失衡，但非透析依赖型CKD （NDD-CKD）患者血清镁水平及其与矿物质-骨骼代谢紊乱（CKD- mbd）关系的研究仍相对有限。本研究旨在探讨非透析依赖型CKD患者不同阶段血清镁水平的变化，并评价其与矿物质代谢指标（钙、磷、iPTH、碱性磷酸酶）的关系。方法：回顾性分析2017年3月至2019年12月邯郸市第一医院收治的156例3-5期CKD （G3-G5）患者的资料。分析血清镁、钙、磷、完整甲状旁腺激素（iPTH）、碱性磷酸酶（AKP）水平。根据血清镁水平将患者分为低镁血症组、正常镁血症组和高镁血症组。分析了镁水平与磷、iPTH和AKP水平的相关性。结果：血清镁水平在CKD G3至G5期呈上升趋势，但该趋势无统计学意义。G3、G4、G5期低镁血症发生率分别为0%、6.82%、15.07%，高镁血症发生率分别为5.13%、13.64%、30.14%。血清镁水平与血清钙和钙磷产物呈显著正相关，而与血清磷和iPTH水平无相关性。结论：随着CKD严重程度的增加，镁代谢紊乱逐渐增加，G5期患病率最高。这些发现表明，血清镁水平的变化可能影响CKD-MBDs的发生和进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Risk Management and Healthcare Policy Medicine-Public Health, Environmental and Occupational Health

CiteScore

6.20

自引率

2.90%

发文量

242

审稿时长

16 weeks

期刊介绍： Risk Management and Healthcare Policy is an international, peer-reviewed, open access journal focusing on all aspects of public health, policy and preventative measures to promote good health and improve morbidity and mortality in the population. Specific topics covered in the journal include: Public and community health Policy and law Preventative and predictive healthcare Risk and hazard management Epidemiology, detection and screening Lifestyle and diet modification Vaccination and disease transmission/modification programs Health and safety and occupational health Healthcare services provision Health literacy and education Advertising and promotion of health issues Health economic evaluations and resource management Risk Management and Healthcare Policy focuses on human interventional and observational research. The journal welcomes submitted papers covering original research, clinical and epidemiological studies, reviews and evaluations, guidelines, expert opinion and commentary, and extended reports. Case reports will only be considered if they make a valuable and original contribution to the literature. The journal does not accept study protocols, animal-based or cell line-based studies.